home / stock / prvcf / prvcf quote
Last: | $0.011 |
---|---|
Change Percent: | -0.69% |
Open: | $0.0146 |
Close: | $0.011 |
High: | $0.0146 |
Low: | $0.011 |
Volume: | 434,000 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.011 | $0.0146 | $0.011 | $0.0146 | $0.011 | 434,000 | 05-03-2024 |
$0.0145 | $0.0145 | $0.0145 | $0.0145 | $0.0145 | 330 | 05-02-2024 |
$0.0147 | $0.0182 | $0.0147 | $0.0182 | $0.0146 | 135,500 | 05-01-2024 |
$0.018164 | $0.0145 | $0.018164 | $0.018164 | $0.0145 | 16,785 | 04-30-2024 |
$0.0145 | $0.0145 | $0.0145 | $0.0145 | $0.0145 | 1,785 | 04-29-2024 |
$0.0147 | $0.0147 | $0.0147 | $0.0147 | $0.0147 | 20,000 | 04-26-2024 |
$0.01624 | $0.01624 | $0.01624 | $0.01624 | $0.01624 | 2,000 | 04-23-2024 |
$0.0186 | $0 | $0.0186 | $0 | $0 | 2 | 04-22-2024 |
$0.0186 | $0.01435 | $0.0186 | $0.0186 | $0.01435 | 11,100 | 04-18-2024 |
$0.0146 | $0.0189 | $0.0146 | $0.0189 | $0.0146 | 67,500 | 04-17-2024 |
$0.0146 | $0.0143 | $0.0146 | $0.0146 | $0.0143 | 46,000 | 04-16-2024 |
$0.019 | $0.019 | $0.019 | $0.019 | $0.019 | 5,000 | 04-15-2024 |
$0.01815 | $0.01815 | $0.01815 | $0.01815 | $0.01815 | 940 | 04-12-2024 |
$0.01675 | $0.019 | $0.01675 | $0.019 | $0.01675 | 120,001 | 04-11-2024 |
$0.01445 | $0.019 | $0.01445 | $0.01905 | $0.0143 | 181,000 | 04-10-2024 |
$0.019 | $0.0191 | $0.019 | $0.0191 | $0.0142 | 614,810 | 04-09-2024 |
$0.0148 | $0.0142 | $0.0148 | $0.0178 | $0.0142 | 11,422 | 04-08-2024 |
$0.016 | $0.0179 | $0.016 | $0.0179 | $0.016 | 63,750 | 04-05-2024 |
$0.0169 | $0.0186 | $0.0169 | $0.0186 | $0.0169 | 12,650 | 04-04-2024 |
$0.0156 | $0.0145 | $0.0156 | $0.0156 | $0.0145 | 15,250 | 04-02-2024 |
News, Short Squeeze, Breakout and More Instantly...
PreveCeutical Medical Inc Company Name:
PRVCF Stock Symbol:
OTCMKTS Market:
Vancouver, British Columbia--(Newsfile Corp. - May 2, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the " Company " or " PreveCeutical ") announces that the Company has missed the filing deadline of April 29, 2024 to file the Company's audited annual financ...
2023-12-04 10:00:34 ET %Obesity and diabetes have become a problem for developed world countries. To address the global rise of these issues, this company is pursuing a dual-gene therapy strategy using proprietary bionanotechnological approaches. The rational design of tissue-targeted b...
PREVECEUTICAL INITIATES PREPARATION OF PROOF-OF-CONCEPT PRECLINICAL STUDY FOR ITS DIABETES & OBESITY DUAL GENE THERAPY PROGRAM PREVECEUTICAL INITIATES PREPARATION OF PROOF-OF-CONCEPT PRECLINICAL STUDY FOR ITS DIABETES & OBESITY DUAL GENE THERAPY PROGRAM Canada NewsWire ...